Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
2017 · New England Journal of Medicine · 7,515 citations
https://doi.org/10.1056/nejmoa1611925
G
Greg Fulcher
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
90
Papers
16.7K
Citations
36
h-index
51
i10-index
Greg Fulcher is an academic researcher from Royal North Shore Hospital. The author has contributed to research in topics: Diabetes Treatment and Management & Diabetes Management and Research & Pancreatic function and diabetes. The author has an h-index of 36, co-authored 77 publications.
Papers by this author
worksDulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
2019 · The Lancet · 2,820 citations
https://doi.org/10.1016/s0140-6736(19)31149-3
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
2019 · The Lancet · 600 citations
https://doi.org/10.1016/s0140-6736(19)31150-x
Primary and tertiary health professionals’ views on the health-care of patients with co-morbid diabetes and chronic kidney disease – a qualitative study
2016 · BMC Nephrology · 38 citations
https://doi.org/10.1186/s12882-016-0262-2
Efficacy and Safety of IDegAsp Versus BIAsp 30, Both Twice Daily, in Elderly Patients with Type 2 Diabetes: Post Hoc Analysis of Two Phase 3 Randomized Controlled BOOST Trials
2018 · Diabetes Therapy · 11 citations
https://doi.org/10.1007/s13300-018-0531-0
Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program
2021 · Diabetologia · 10 citations
https://doi.org/10.1007/s00125-021-05524-1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat